SecBot SecBot
SECBOTREPLAY Home › Report › TEVA

TEVA · A federal magistrate judge partially granted and partially denied…

TEVA PHARMACEUTICAL INDUSTRIES LTD · COURT-RULING filed Jul 14, 2026 at 20:00 ET

At the news

NEUTRALIMPACT 2/10

COURT-RULING filed Jul 14, 2026 at 20:00 ET

A federal magistrate judge partially granted and partially denied Corcept Therapeutics' motion to compel discovery from Teva's CEO Richard Francis. Teva's CEO must sit for a limited two-hour deposition regarding his critique of Teva's generic mifepristone promotion strategies, but Teva is not required to produce his custodial documents. This is a routine procedural discovery ruling in an ongoing antitrust case with no immediate financial impact.

  • Teva is the plaintiff in an antitrust case against Corcept regarding generic mifepristone for Cushing's syndrome.
  • Corcept sought to depose Teva's CEO Richard Francis and obtain his documents; the court granted a limited 2-hour deposition on one topic and denied document production.
  • The deposition is limited to Mr. Francis's critique of Teva's strategy for promoting generic mifepristone and his ideas for solutions.
  • Fact discovery in the case closed on May 15, 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access